TY - JOUR
KW - Adult
KW - Analgesics, Opioid/administration & dosage/adverse effects
KW - buprenorphine
KW - Buprenorphine/administration & dosage/adverse effects
KW - craving
KW - Craving/drug effects
KW - Double-Blind Method
KW - Humans
KW - Inpatients
KW - Iran
KW - Male
KW - Opiate Substitution Treatment/adverse effects/methods
KW - opioid dependence
KW - opioid withdrawal
KW - Opioid-Related Disorders/diagnosis/psychology/rehabilitation
KW - Substance Withdrawal Syndrome/diagnosis/drug therapy/psychology
KW - Time Factors
KW - Treatment Outcome
AU - J. Ahmadi
AU - M. S. Jahromi
AU - D. Ghahremani
AU - E. D. London
A1 - 
AB - BACKGROUND: Opioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a problem if the medication is given outside a hospital setting. OBJECTIVE: The objective of this research is to evaluate the effect of a single, high dose of buprenorphine on craving in opioid-dependent patients over 5 days of abstinence from use of other opioids. The primary goal was to determine the safety and efficacy of buprenorphine during withdrawal in a hospital setting. METHODS: Ninety men who used opium, heroin, or prescribed opioids and met DSM-5 criteria for opioid use disorder (severe form) were randomized to three groups (n = 30 per group) to receive a single, sublingual dose of buprenorphine (32, 64, or 96 mg). The study was conducted in an inpatient psychiatric ward, with appropriate precautions and monitoring of respiratory and cardiovascular measures. Buprenorphine was administered when the patients were in moderate opiate withdrawal, as indicated by the presence of four to five symptoms. A structured clinical interview was conducted, and urine toxicology testing was performed at baseline. Self-reports of craving were obtained at baseline and on each of the 5 days after buprenorphine administration. FINDINGS: Craving decreased from baseline in each of the three groups (p < 0.0001), with a significant interaction between group and time (p < 0.038), indicating that groups with higher doses of buprenorphine had greater reduction. CONCLUSIONS: A single, high dose of buprenorphine can reduce craving during opioid withdrawal; additional studies with follow-up are warranted to evaluate safety.
BT - Trials
C5 - Opioids & Substance Use
CP - 1
CY - England
DO - 10.1186/s13063-018-3055-z
IS - 1
JF - Trials
N2 - BACKGROUND: Opioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a problem if the medication is given outside a hospital setting. OBJECTIVE: The objective of this research is to evaluate the effect of a single, high dose of buprenorphine on craving in opioid-dependent patients over 5 days of abstinence from use of other opioids. The primary goal was to determine the safety and efficacy of buprenorphine during withdrawal in a hospital setting. METHODS: Ninety men who used opium, heroin, or prescribed opioids and met DSM-5 criteria for opioid use disorder (severe form) were randomized to three groups (n = 30 per group) to receive a single, sublingual dose of buprenorphine (32, 64, or 96 mg). The study was conducted in an inpatient psychiatric ward, with appropriate precautions and monitoring of respiratory and cardiovascular measures. Buprenorphine was administered when the patients were in moderate opiate withdrawal, as indicated by the presence of four to five symptoms. A structured clinical interview was conducted, and urine toxicology testing was performed at baseline. Self-reports of craving were obtained at baseline and on each of the 5 days after buprenorphine administration. FINDINGS: Craving decreased from baseline in each of the three groups (p < 0.0001), with a significant interaction between group and time (p < 0.038), indicating that groups with higher doses of buprenorphine had greater reduction. CONCLUSIONS: A single, high dose of buprenorphine can reduce craving during opioid withdrawal; additional studies with follow-up are warranted to evaluate safety.
PP - England
PY - 2018
SN - 1745-6215; 1745-6215
SP - 675
T1 - Single high-dose buprenorphine for opioid craving during withdrawal
T2 - Trials
TI - Single high-dose buprenorphine for opioid craving during withdrawal
U1 - Opioids & Substance Use
U2 - 30526648
U3 - 10.1186/s13063-018-3055-z
VL - 19
VO - 1745-6215; 1745-6215
Y1 - 2018
ER -